SELLAS Life Sciences (SLS) Non-Current Assets (2010 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Non-Current Assets of $3.0 million for Q1 2026, up 0.84% year-over-year from $3.0 million in Q1 2025, and down 4.02% quarter-over-quarter from $3.1 million in Q4 2025.
SELLAS Life Sciences (SLS) Non-Current Assets (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Non-Current Assets for 17 consecutive years, with $3.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 0.84% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $11.5 million (up 1.13% YoY), while the FY2025 annual figure was $3.1 million, up 0.93% from the prior year.
- Non-Current Assets slipped to $3.0 million in Q1 2026 per SLS's latest filing, from $3.1 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $3.6 million in Q1 2022 and bottomed at $2.5 million in Q3 2024.
- Historically, Non-Current Assets has averaged $3.0 million across 5 years, with a median of $3.0 million in 2026.
- Annual changes were most pronounced in 2022 — Non-Current Assets tumbled 62.17% — and 2024, when it rose 1.9%.
- SELLAS Life Sciences' Non-Current Assets stood at $3.2 million in 2022, then decreased by 4.39% to $3.0 million in 2023, then rose by 1.9% to $3.1 million in 2024, then increased by 0.93% to $3.1 million in 2025, then dropped by 4.02% to $3.0 million in 2026.
- Business Quant data shows SLS's Non-Current Assets at $3.0 million in Q1 2026, $3.1 million in Q4 2025, and $2.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | 2.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.88 Mn |
| Mar 31, 2026 | 3.01 Mn |
| Dec 31, 2025 | 3.13 Mn |
| Sep 30, 2025 | 2.50 Mn |
| Jun 30, 2025 | 2.86 Mn |
| Mar 31, 2025 | 2.98 Mn |
| Dec 31, 2024 | 3.11 Mn |
| Sep 30, 2024 | 2.47 Mn |
| Jun 30, 2024 | 2.82 Mn |
| Mar 31, 2024 | 2.93 Mn |
| Dec 31, 2023 | 3.05 Mn |
| Sep 30, 2023 | 2.88 Mn |
| Jun 30, 2023 | 2.99 Mn |
| Mar 31, 2023 | 3.08 Mn |
| Dec 31, 2022 | 3.19 Mn |
| Sep 30, 2022 | 3.40 Mn |
| Jun 30, 2022 | 3.47 Mn |
| Mar 31, 2022 | 3.60 Mn |
| Dec 31, 2021 | 3.23 Mn |
| Sep 30, 2021 | 8.98 Mn |